By targeting two pathways at once, we may outsmart the immune system
For patients with Crohn's disease or ulcerative colitis who have exhausted every available treatment, medicine has long offered little more than diminishing returns and quiet resignation. A combination therapy tested in Phase 2b trials — targeting two inflammatory pathways simultaneously — has now produced remission rates dramatically higher than either component alone, particularly among those who had already failed multiple prior treatments. Presented at Digestive Disease Week in May 2026, the findings suggest that when a disease learns to outmaneuver a single drug, the answer may lie not in finding a better drug, but in closing two doors at once.
- Thousands of IBD patients have reached the end of the treatment ladder, their inflammation persisting despite biologics, oral medications, and every tool modern gastroenterology offers.
- JNJ-78934804 combines two existing drugs — guselkumab and golimumab — into a single fixed-dose formulation that blocks two separate inflammatory pathways simultaneously, a concept simple in theory but novel in practice.
- In trials of nearly 1,300 patients, the high-dose combination achieved remission rates 20 to 40 percentage points higher than single therapies among those who had already failed two or more prior treatments.
- Beyond symptom relief, the drug showed measurable endoscopic and tissue-level healing, while maintaining a safety profile no worse than either component used alone.
- Phase 3 trials are now on the horizon, carrying with them the weight of hope for a population that has, until now, had almost nowhere left to turn.
For years, gastroenterologists have watched the same pattern repeat: a patient with Crohn's disease or ulcerative colitis arrives having already tried everything, and still the inflammation persists. Until now, those patients had almost nowhere left to turn.
Two studies presented at Digestive Disease Week in May 2026 tested a different approach. JNJ-78934804 combines two existing biologics — guselkumab, which targets IL-23, and golimumab, an anti-TNF agent — into a single fixed-dose formulation designed to block two inflammatory pathways at once. Neither drug is new. But using them together appears to achieve something neither can accomplish alone.
The Crohn's trial enrolled 693 patients and the ulcerative colitis trial enrolled 572, with roughly half of all participants having already failed two or more prior systemic therapies. Among that hardest-to-treat group, the high-dose combination produced remission rates more than 20 percentage points above guselkumab and nearly 40 above placebo in Crohn's patients. The ulcerative colitis results were similarly striking, with additional gains in endoscopic and tissue-level healing.
Lead researchers Bruce Sands and Maria Abreu described the logic plainly: each successive IBD therapy produces diminishing returns, but targeting two pathways simultaneously prevents the disease from finding a workaround. Critically, safety remained comparable to either drug used alone — a vital consideration for patients already burdened by chronic illness.
The combination is now advancing to Phase 3 trials. For patients who have exhausted every other option, the data offers something that has been scarce: a meaningful chance at controlling a disease that has already resisted everything else.
For years, gastroenterologists have watched the same pattern repeat: a patient with Crohn's disease or ulcerative colitis arrives at the clinic having already tried everything—multiple biologics, oral medications, the full arsenal of modern IBD treatment. And still, their inflammation persists. The disease has outsmarted each drug thrown at it, one after another. Until now, those patients had almost nowhere left to turn.
Two new studies presented at Digestive Disease Week in May 2026 suggest a different approach might work where single therapies fail. Researchers tested JNJ-78934804, a combination drug that does something relatively simple in concept but novel in execution: it blocks two separate inflammatory pathways at the same time. One component, guselkumab, targets a protein called IL-23. The other, golimumab, is an anti-TNF agent. Neither is new. But using them together, in a single fixed-dose formulation, appears to achieve something neither can accomplish alone.
The Crohn's disease trial enrolled 693 patients; the ulcerative colitis trial enrolled 572. Roughly half of all participants had already failed two or more prior systemic therapies—a population that represents one of medicine's most stubborn clinical problems. These were people for whom the usual progression of treatment had reached a dead end. Researchers randomized them to receive either a placebo, one of the two existing biologics alone, or the combination at one of three doses.
The results were clearest in the patients who needed them most. Among those who had failed two or more prior treatments, the high-dose combination produced clinical remission rates more than 20 percentage points higher than guselkumab and nearly 40 percentage points higher than placebo in the Crohn's cohort. In the ulcerative colitis group, the gap was similarly striking: more than 20 percentage points above guselkumab, nearly 20 above placebo. The combination also showed meaningful improvements in endoscopic healing and, in the UC trial, in histologic remission—actual tissue-level repair.
Bruce Sands, the lead researcher on the Crohn's study and chief of gastroenterology at Mount Sinai, framed the finding plainly: each successive IBD therapy produces diminishing returns. By combining two mechanisms, the team achieved what appeared to be additive efficacy without adding safety risk. Maria Abreu, who led the ulcerative colitis trial at Cedars-Sinai, described it as outsmarting the immune system—targeting two pathways simultaneously so the disease cannot simply find a workaround.
Safety remained comparable to either drug used alone. Serious adverse events were uncommon in both trials and primarily gastrointestinal in nature. That matters enormously for a population already burdened by disease. The researchers say the combination is ready to move into Phase 3 trials, the larger studies that will determine whether these Phase 2b results hold up and whether the drug can eventually reach patients.
For the thousands of IBD patients who have exhausted conventional options, the data offers something that has been scarce: genuine hope. Not a cure, not even remission guaranteed. But a meaningful chance at controlling a disease that has already resisted everything else.
Citações Notáveis
By combining two mechanisms of action, we're seeing efficacy that appears to be additive—without increasing safety risk.— Bruce E. Sands, MD, lead author of the Crohn's disease study
By targeting two pathways at once, we may be able to 'outsmart' the immune system and achieve better outcomes.— Maria T. Abreu, MD, lead author of the ulcerative colitis study
A Conversa do Hearth Outra perspectiva sobre a história
Why does combining two drugs work better than either one alone? Isn't that just doubling the dose?
No—it's fundamentally different. Each drug blocks a different inflammatory pathway. One patient's immune system might compensate for blocking TNF by ramping up IL-23 signaling. The combination prevents that escape route.
So the disease is actually strategic? It adapts?
In a sense, yes. The immune system finds workarounds. That's why patients fail therapy after therapy. By blocking two pathways simultaneously, you close off the adaptation.
What about side effects? Aren't you doubling the risk?
That's what makes this striking. The safety profile was comparable to either drug alone. No new safety signal emerged. That's rare in combination therapy.
Who benefits most from this?
The patients who have already failed two or more treatments. That's roughly half the IBD population at any given time. For them, options are genuinely limited. This gives them somewhere to go.
Is this a cure?
No. It's remission—controlling the inflammation so the disease stops destroying the gut. For someone who's exhausted other options, that's transformative.
What happens next?
Phase 3 trials. Larger studies to confirm these results hold up. If they do, the drug could reach patients within a few years.